New data on SIR-Spheres Y-90 resin microspheres shows benefits in patients with liver-dominant metastatic Colorectal Cancer- Sirtex
New data suggests that patients with liver-dominant metastatic Colorectal Cancer treated first-line with the combination of mFOLFOX6 and SIR-Spheres Y-90 resin microspheres, from Sirtex, in the recently published SIRFLOX study experienced a much more profound response to treatment in the liver than those who received chemotherapy alone. According to Depth of Response (DpR) analysis, a relatively new methodology that has been shown to correlate with overall survival (OS) and post-progression survival in earlier mCRC studies, there was a significantly greater Depth of Response (75.0% vs. 67.8% mean reduction in liver tumour burden) in patients who received SIR-Spheres Y-90 resin microspheres combined with chemotherapy. Patients also had a statistically significant, two-month longer time to DpR or maximal tumour shrinkage (median 266 vs. 206 days), compared to those who received chemotherapy alone.
The analysis also revealed that the treatment effect following SIR-Spheres Y-90 resin microspheres was most evident in the patients who entered the study with a greater baseline liver tumour burden (more than 12% of the liver having been replaced by tumour, a statistical cut-point that was pre-determined in order to identify potential predictors of DpR). This group of more compromised patients, representing over half the patients in SIRFLOX, experienced a statistically significant, 20% greater DpR (77.5% vs. 57.2%) and over three-month longer time to DpR (median 298 vs. 196 days) compared to those treated with chemotherapy alone. SIR-Spheres Y-90 resin microspheres was also associated with a doubling of median Progression-Free Survival (PFS) in the liver by competing risk analysis (27.2 vs. 13.1 months) in these patients.
Conversely, patients who had a smaller liver tumour burden (less than 12%) on study entry were more than six times more likely to experience a complete response or disappearance of all liver tumours following SIR-Spheres Y-90 resin microspheres compared to those who received only chemotherapy (11.3% vs. 1.7%). Results were presented at the European Society of Medical Oncology's 18th World Congress on Gastrointestinal Cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins